Precision medicine

Protein
#Biomarkers #Clinical trials #Collaboration #Eurofins Genomics #Olink #Partnership #Precision medicine #Proteomics

Eurofins Genomics and Olink partner to advance proteomics research

Eurofins Genomics has adopted Olink technology to advance proteomics research and accelerate its precision medicine programmes. The collaboration is designed to bolster the company’s offerings in the fields of research, population health, and regulated clinical trials. Olink Explore HT is the company's latest solution for high-throughput proteomics, allowing scientists to… Read More

#Business & Investment #News

AI and genomics
#AI / data analytics / healthtech / informatics #DNA #Genetics / genomes #Precision medicine #Rare disease

New podcast on the future for genomics and big data

This is the latest episode of the free DDW narrated podcast, “What lies in the future for genomics and big data?”, which covers two articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “What’s the next step in big… Read More

#News

Gastrointestinal tract
#Drug delivery #Gastrointestinal #Precision medicine #Triastek

3D-printed oral treatment for ulcerative colitis proves successful

A first in human study of a 3D printing drug product, T21, designed to treat moderate to severe ulcerative colitis (UC), has reported positive results. Imaging results from the study confirmed that T21 tablets are precisely delivered and released to the target site (the colon) for… Read More

#News

The microbiome
#Drug discovery #Gut microbiome #Microbiome #Precision medicine

The microbiome in precision medicine

Listen to this article on the DDW Podcast: An industry overview of the role of the microbiome in precision medicine, and its interplay with research tools, diagnostics, and therapeutic development. By Katie Gillette, Senior Project Leader, Eliza French, Analyst, and Graham Friedman, Analyst, DeciBio. The human microbiome refers to the vast… Read More

#Exclusive Content #Trends & Analysis

#Artificial intelligence (AI) #Cancer research #Collaboration #Oncology #Precision medicine #The Institute of Cancer Research #Vivan Therapeutics

AI discovery collaboration targets precision cancer drugs

Researchers will combine expertise in drug discovery, artificial intelligence (AI), and experimental cancer models and platforms in a new programme to design the precision cancer drugs of the future. Under an academic and commercial collaboration between The Institute of Cancer Research, London, the Bellvitge Biomedical Research… Read More

#Cancer Research #News

#Artificial intelligence (AI) #Cell and gene therapy #Machine learning #Monoclonal antibodies #mRNA #Precision medicine

Right on target: The shift to precision pharmaceuticals

By DDW Editor Reece Armstrong. If there’s one thing I would take from the Summer 2023 issue of Drug Discovery World, it would be that the application of technologies and processes throughout the pharmaceutical industry are changing how scientists pursue the development of therapies. Artificial intelligence (AI), gene editing, synthetic… Read More

#Exclusive Content

Cancer research lab
#Cancer research #Cancer Research UK #Clinical trial design #Oncology #Precision medicine

Cancer Research UK joins precision cancer medicine consortium

Cancer Research UK has joined the PRIME-ROSE project, a Europe-wide effort to boost patient access to precision cancer medicine (PCM). The PRIME-ROSE consortium consists of 24 partners, including nine beneficiaries and fifteen associated partners who will come together over the course of five years and work… Read More

#Cancer Research #News

#Cancer immunotherapy #Cancer research #Cancer Research Month #Diagnostics #Immunotherapy #Oncology #Precision medicine

National Cancer Research Month: Celebrating drug discovery innovation

From antibody-drug conjugates and RNA, to CRISPR and CAR-T therapy, DDW asked the drug discovery industry what the most important development in oncology over the last five years has been. As the US National Cancer Research Month draws to a close, we asked experts from across the industry “What do… Read More

#Cancer Research #Exclusive Content

#ALS #LifeArc #Neuroscience #Partnership #Precision medicine #PrecisionLife

Partners to advance precision medicines for MND

Not-for-profit medical research organisation LifeArc and techbio company PrecisionLife have agreed a strategic R&D collaboration to accelerate the discovery of targeted treatments for motor neurone disease (MND). MND is also known as amyotrophic lateral sclerosis (ALS) and Lou Gehrig’s disease. The collaboration will accelerate… Read More

#News

#Clinical research #Clinical trials #Drug discovery #Precision medicine

New podcast on how precision medicine will transform clinical trials

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this latest episode, DDW’s Megan Thomas is in conversation with… Read More

#News

AI brain
#AI / data analytics / healthtech / informatics #Drug discovery #Funding #MultiOmic Health #Precision medicine #Seed funding #Start-ups

AI platform focuses on precision medicines for metabolic syndromes

AI drug discovery company MultiOmic Health has closed a £5 million ($6.2 million) seed funding extension round to build a precision therapeutics discovery platform for metabolic syndrome-related medical conditions. The round was led by London-based Hoxton Ventures, with participation from Ada Ventures, MMC Ventures and Verve… Read More

#News #Start-up Zone

Genetics
#Cancer research #Gene mutation #Genetics / genomics #Oncology #Precision medicine

3D genomics and targeted cancer therapies

Listen to this article on the DDW Podcast: Anthony Schmitt, PhD, Senior Vice President, Science at Arima Genomics, discusses the applications of 3D genomics in cancer research. Efforts to fulfil the promise of precision medicine, including the use of targeted cancer therapies, necessitate that patients be treated based on the specific genetic… Read More

#Cancer Research #Exclusive Content

Antibody drug conjugate
#AI / data analytics / healthtech / informatics #Antibodies #Antibody drug conjugate (ADC) #Big pharma #Drug development #Precision medicine

A personal view on antibody drug development

Oliver Schon, PhD, is VP Research & Development at BiVictriX Therapeutics, a UK-based emerging drug discovery and development company generating a pioneering first-in-class next-generation ADC anti-cancer therapeutics which exhibit superior selectivity towards cancer. Dr Schon is applying his broad expertise from lead discovery to manufacture in order to progress differentiated,… Read More

#Exclusive Content

#Aptamer Group #Aptamers #Automation #Drug delivery #Gene delivery #Gene therapy #Molecular Biology #Oncology #Precision medicine #Turning Science into Business

Turning science into business: An optimised alternative to antibodies

From humble beginnings in the founder’s basement, UK-based Aptamer Group is now supplying its Optimer binders to clients across big pharma. DDW’s Diana Spencer caught up with co-founder and CEO Dr Arron Tolley. DS: What motivated you and Dr David Bunka, CTO, to create Aptamer and did you imagine you would… Read More

#Exclusive Content

#Data #Drug development #Gene sequencing #Genome sequencing #Genomics #Healthcare #Precision medicine #Trusted research environment

Why Trusted Research Environments are key to the future of genomics  

Genomics is driving a revolution in drug development and, in the long run, the state of public healthcare. Advances in sequencing are leading to scientific breakthroughs in preventative care, faster diagnoses, and proactive medical interventions. Jack Dix, Head of Healthcare Strategy and Consulting at Kainos, expands.  Genetic insights are also… Read More

#Exclusive Content #Opinion #Trends & Analysis

#Avacta #Cancer research #CAR-T #Cell therapy #Immunotherapy #Oncology #Precision medicine #T cell activation #Therapeutic targets

Precision cancer therapies: Where are we?

DDW’s Diana Spencer reports on the recent Avacta Therapeutics Science Day, which explored the latest exciting developments in precision and targeted treatments for cancer and asked what advances the future might bring. The Avacta Therapeutics Science Day brought together senior company scientists and international oncology experts to provide an overview… Read More

#Cancer Research #Exclusive Content